Promise of in vivo drug production sets off an mRNA arms race

Biotech researchers have long strived to use the body's natural resources to treat disease, whether by galvanizing the immune system or spurring the production of helpful materials. And thanks to some recent breakthroughs, a bevy of companies are pushing forward with messenger RNA, or mRNA, projects designed to turn human cells into in vivo drug factories. As Reuters notes, private biotechs CureVac, Moderna Therapeutics and BioNTech are developing mRNA treatments that can key the production of therapeutic proteins inside the body, raising hundreds of millions of dollars in venture investments and partnering dollars along the way. More

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.